Similar Items: A pharmacokinetic and antimalarial efficacy evaluation of pyridodibemequines and their metabolites
- Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated Falciparum malaria
- Population pharmacokinetics and pharmacokinetic-pharmacodyamic modeling of antitubercular drugs
- Screening of actinobacteria for novel antimalarial compounds
- Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment
- Antimalarial activity and pharmacokinetic properties of new chemical entities
- Pharmacogenomics and pharmacokinetics of dolutegravir and tenofovir in Southern Africans living with HIV
Author: Wiesner, Lubbe
- Development and validation of selective and sensitive LC-MS/MS Methods for determination of para-aminosalicyclic acid and cycloserine/terizidone applicable to clinical studies for the treatment of tuberculosis
- Determination of total, unbound, and intracellular concentrations of the antiretroviral drugs Efavirenz, Lopinavir, and Ritonavir
- Screening rare filamentous actinobacteria for novel antimycobacterial compounds
- Simultaneous quantification of first-line anti-tuberculosis drugs and metabolites in human plasma
- A pharmacokinetic and antimalarial efficacy evaluation of pyridodibemequines and their metabolites
- Isolation and characterisation of antiplasmodial compounds from Xerophyta species and the bioavailability, metabolic and efficacy evaluation of 9-0-acetylhydnocarpin in a mouse model